1. At a Glance – The Calm Before the Vizag Storm?
Blue Jet Healthcare is currently trading at ₹357, down a brutal 37.4% in the last 3 months and a jaw-dropping 51.9% over 1 year. Market cap stands at ₹6,190 crore.
And here’s the twist — this is a company with:
- ROCE: 39.8%
- ROE: 30.2%
- Debt to Equity: 0.02 (basically debt-free)
- OPM: 34.4%
- P/E: 21.1 (below industry PE of 27.9)
But then came Q3 FY26.
- Quarterly Sales: ₹192 crore (↓39.6% YoY)
- Quarterly PAT: ₹40 crore (↓59.4% YoY)
- EBITDA Margin: 24% (vs 39% in peak quarters)
So what happened?
Did the business break?
Did customers run away?
Or is this just pharma’s classic “channel destocking drama”?
Meanwhile, management quietly announces a ₹1,000 crore Vizag greenfield capex plan, 102-acre land acquisition, and expansion into GLP-1, peptides and advanced APIs.
Stock crashes. Company expands.
Classic Indian market paradox.
Let’s investigate.
2. Introduction – When a 40% Revenue Drop Doesn’t Mean the Business is Broken
Blue Jet Healthcare isn’t your regular generic pharma company. It doesn’t sell tablets you see on pharmacy shelves.
It sells ingredients that go inside ingredients that go inside drugs.
Specifically:
- Contrast media intermediates (used in CT scans and MRIs)
- High-intensity sweeteners (saccharin)
- Pharma intermediates & APIs
And here’s the spicy part — 67.7% of FY24 revenue comes from contrast media intermediates.
Contrast media is a USD 5.9 billion global market, and top players control 75% of it. Blue Jet supplies to giants like:
- GE Healthcare
- Guerbet Group
- Bracco Imaging
Now Q3 FY26 numbers came in and investors panicked.
Revenue down 40% YoY.
PAT down 39% YoY.
Margins compressed.
But management says:
- Channel destocking.
- Revenue recognition cut-offs.
- Supply chain realignment.
- Inventory write-offs (~1% impact).
Translation in desi terms:
“Customer ne maal liya tha, ab thoda ruk ke use kar raha hai.”
The key question:
Is this temporary inventory adjustment… or structural decline?
Keep reading.
3.
